Posts

For pet dogs, ‘running with the pack’ may be the best p...

What exactly makes for a fit Fido? And how does a dog’s environment factor into ...

MethaneMapper is poised to solve the problem of underre...

(Santa Barbara, Calif.) — Wildfires. Many see them as purely destructive forces,...

Researchers to explore potential of new treatment again...

EL PASO, Texas (June 8, 2023) – Researchers from The University of Texas at El P...

University of Arizona launching computer science and en...

Right now, United States employers are unable to fill around 1 million computer ...

New method takes the uncertainty out of oxide semicondu...

Tokyo, Japan – 3D integrated circuits are a key part of improving the efficiency...

Preparing the stage for 6G: A fast and compact transcei...

New transceiver design capable of both transmission and reception at frequencies...

Novartis spinoff Sandoz to establish HQ in Basel

Novartis’ generics spinoff, Sandoz, has announced that it will be setting up its...

Novartis drug helps stop breast cancer’s return in a la...

According to clinical study findings, when administered following surgery in adu...

AstraZeneca Adds Imfinzi and Lynparza to Ovarian Cancer...

AstraZeneca’s usage limitation in ovarian cancer has been a stumbling block desp...

FDA clears narrow use of prostate cancer therapy Lynparza

Lynparza can now be used in conjunction with Zytiga from Johnson & Johnson and a...

Japanese drugmaker Eisai undergoingn investigation for ...

Following the recent trend among Japanese firms, such as West Japan Railway, Tok...

FibroGen’s DMD drug fails phase 3 trial, adding to clin...

FibroGen continues to face challenges in its clinical endeavors, now extending i...

AstraZeneca’s Andexxa succeeds in postmarket study, aim...

AstraZeneca’s Andexxa has reached the endpoint of its study  has made the decisi...

Eli Lilly achieving significant gains in obesity results

The recent rallying of Lilly’s market value has come as the result of two major ...

US FDA expands approval for Merck’s PREVYMIS (letermovir)

The FDA approval was supported by a double-blind, active comparator-controlled n...

EC grants marketing authorisation for Fennec’s Pedmarqsi

The regulatory approval comes after a positive opinion issued by the European Me...